- Indivior presented data over the weekend to help the healthcare community and others understand the challenges faced by patients with opioid use disorder and potential ways to overcome them.

Data from two new studies, included insights into dosing of company's once-monthly Sublocade injection for subcutaneous use, for the treatment of moderate to severe opioid use disorder in patients who inject opioids, and reports on the impact of therapeutic plasma concentrations of buprenorphine in inhibiting the respiratory depression caused by fentanyl.

The results were reported at the 50 Annual Conference of the American Society of Addiction Medicine (ASAM) in Orlando, Florida and follow Friday's announcement of results from the company's Recover study and the 18-month long-term safety study.

Story provided by